| SEC For | m 4 FORM | 4 | UNITED ST | ATE | S SE | | | | | NGE C | OMMI | SSION | | | | | |
|--|---|--|---|---|---|-----------|--------|--|---------------------|---|--|--|--|----|--|---|--|
| | | | | | | V | /ashii | ngton, D.C. 20 | 0549 | | | | OMB APPROVAL | | | | |
| Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). | | | | | suant t | o Sectior | n 16(a | a) of the Secu | rities Exchar | | SHIP | Estima | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | | | | |
| 1. Name and Address of Reporting Person* $\underline{Kelley \ Susan \ L.}$ | | | | | 2. Issuer Name and Ticker or Trading Symbol Dare Bioscience, Inc. [DARE] | | | | | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner | | | | | |
| (Last) (First) (Middle) 3655 NOBEL DRIVE | | | | | 3. Date of Earliest Transaction (Month/Day/Year) 06/24/2021 | | | | | | | Officer below) | (give title Other (sj below) | | | pecify | |
| SUITE 260 | | | | 4. | If Amer | ndment, I | Date | of Original Fil | ed (Month/Da | | 6. Individual or Joint/Group Filing (Check Applicable Line) | | | | | | |
| (Street) SAN DIEGO CA 92122 | | | | | | | | | | | | X Form filed by One Reporting Person Form filed by More than One Reporting Person | | | | | |
| (City) (State) (Zip) | | | | | | | | | | | | | | | | | |
| | | Tab | le I - Non-Der | ivativ | e Sec | curities | s Ac | quired, Di | isposed o | of, or Bei | neficial | ly Owned | | | | | |
| 1. Title of Security (Instr. 3) 2. Transa Date (Month/Date) | | | | | Execution Date | | | Code (Ins | | | | Beneficia Owned F | es Forn ally (D) o following (I) (Ir d tion(s) | | rm: Direct or Indirect (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |
| | | | | | | | Code V | Amount | (A) or (D) Price | | Reported Transact (Instr. 3 a | | | | | | |
| | | - | Table II - Deriv (e.g., | | | | | uired, Dis , options, | | | | Owned | | | | | |
| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | ly | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) | |
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | | | | |
| Stock Option (right to buy) | \$1.46 | 06/24/2021 | | A | | 30,000 | | (1) | 06/24/2031 | Common stock | 30,000 | \$0 | 30,000 |) | D | | |

Explanation of Responses:

1. This option will vest in full on the earlier of the first anniversary of the grant date or immediately prior to the issuer's first annual meeting of stockholders occurring after the grant date, subject to the director's continued service as a director, and will become exercisable in full upon a change in control of the issuer.

Remarks:

| /s/Lisa Walters-Hoffert, | |
|--------------------------|--|
| Attorney-in-fact | |

<u>06/24/2021</u>

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.